Current snapshot of the U.S. diabetes epidemic
Diabetes has reached epidemic proportions in the United States. As the number of Americans that are older, heavier, sedentary, and more ethnically diverse has grown, and also as improvements have been made in detection, there has been a steady rise in the overall population with type 2 diabetes.1 Also, some epidemiologists are reporting increases in the number of new cases of children with type 1 diabetes.2
According to the US Centers for Disease Control and Prevention (CDC), National Diabetes Statistics Report, 2014, of the 29.1 million that already have diabetes, 8.1 million are undiagnosed. There are approximately 1.7 million new cases of diabetes per year.3 In a newer, separate study sponsored by Novo Nordisk, the total cost of diabetes (which includes costs for diagnosed diabetes, undiagnosed diabetes, prediabetes, and gestational diabetes) was estimated at $322 billion in 2012, up 48% from $218 billion in 2007, with $244 billion for direct medical expenditures and $78 billion for indirect costs.4 This new study builds upon the costs cited by the CDC, which are for diagnosed diabetes only.3
Currently, there are 86 million adults with prediabetes,3 placing them at high risk for developing type 2 diabetes, with about 90% of them undiagnosed.5
Despite all of these statistics, there are still gaps in research and data. Novo Nordisk has worked with members of the diabetes community to identify and commission research to help fill these gaps and illuminate other areas of interest for advancing public policy. Novo Nordisk is proud to commission and conduct research that helps describe and measure the problems and challenges the U.S. faces in diabetes.